NasVax: Closing Share Purchase Agreement of Protea Vaccine Technologies
Protea has become a fully owned subsidiary of NasVax
Advertisement
NasVax Ltd. announced that it has closed the purchase of 100% of the shares of Protea Vaccine Technologies of Kiryat Shmona Israel. As a result, Protea has become a fully owned subsidiary of NasVax.
In June 2009, Protea announced that it signed a Research and License Option Agreement with GlaxoSmithKline to a set of Protea’s conserved pneumococcal proteins for the development and commercialization of a universal protein-based Streptococcus pneumoniae vaccine.
Protea is developing an next-generation vaccine against diseases caused by Streptococcus pneumoniae, based on widely conserved pneumococcal proteins.